Revance Therapeutics (RVNC) 10-Q 14 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	6-May-15
Document And Entity Information [Abstract]
Entity Registrant Name	Revance Therapeutics, Inc.
Entity Central Index Key	1479290
Current Fiscal Year End Date	-19
Entity Filer Category	Non-accelerated Filer
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		23,946,650

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
CURRENT ASSETS
Cash and cash equivalents	$153,717	$171,032
Restricted cash, current portion	35	75
Prepaid expenses and other current assets	1,937	1,624
Total current assets	155,689	172,731
Property and equipment, net	19,390	19,274
Restricted cash, net of current portion	400	435
Other non-current assets	243	29
TOTAL ASSETS	175,722	192,469
CURRENT LIABILITIES
Accounts payable	2,089	3,149
Accruals and other current liabilities	4,019	4,145
Financing obligation, current portion	319	307
Notes payable, current portion and net of discount	0	2,635
Total current liabilities	6,427	10,236
Financing obligation, net of current portion	513	598
Derivative liabilities associated with Medicis settlement	1,583	1,541
Deferred rent	3,741	3,725
TOTAL LIABILITIES	12,264	16,100
Commitments and Contingencies (Note 8)
STOCKHOLDERS’ EQUITY
Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of March 31, 2015 and December 31, 2014, respectively; 23,944,861 and 23,774,465 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	24	24
Additional paid-in capital	437,633	435,142
Accumulated deficit	-274,199	-258,797
TOTAL STOCKHOLDERS’ EQUITY	163,458	176,369
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$175,722	$192,469

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	95,000,000	95,000,000
Common stock, shares issued (in shares)	23,944,861	23,774,465
Common stock, shares outstanding (in shares)	23,944,861	23,774,465

Condensed_Consolidated_Stateme

Condensed Consolidated Statement of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue	$75	$158
Operating expenses:
Research and development	9,254	7,551
General and administrative	5,996	4,093
Total operating expenses	15,250	11,644
Loss from operations	-15,175	-11,486
Interest income	27	2
Interest expense	-165	-9,841
Change in fair value of derivative liabilities associated with the convertible notes	0	4,032
Changes in fair value of derivative liabilities associated with Medicis settlement	-42	-416
Change in fair value of common stock warrant liability	0	-2,151
Change in fair value of convertible preferred stock warrant liability	0	-210
Loss on settlement of preferred stock warrant	0	-1,356
Other expense, net	-47	0
Net and comprehensive loss	-15,402	-21,426
Net loss attributable to common stockholders (Note 11):
Basic	-15,402	-21,426
Diluted	($15,402)	($21,426)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	($0.65)	($1.93)
Diluted (in dollars per share)	($0.65)	($1.93)
Weighted-average number of shares used in computing net loss per share attributable to common stockholders:
Basic (in shares)	23,535,080	11,092,471
Diluted (in shares)	23,535,080	11,092,471

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($15,402)	($21,426)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	531	488
Amortization of discount on debt and capital leases	5	1,046
Amortization of debt issuance cost	39	52
Revaluation of derivative liabilities associated with convertible notes	0	-4,032
Revaluation of derivative liabilities associated with the Medicis settlement	42	416
Revaluation of common stock warrant liability	0	2,151
Revaluation of convertible preferred stock warrant liability	0	210
Extinguishment of warrant liability upon exercise of put option by warrant holder	0	1,356
Loss on extinguishment of 2013 Notes	0	8,331
Stock-based compensation expense	2,317	810
Interest for 2013 Notes and Essex Notes upon issuance, non-cash	0	271
Capitalized interest	0	-231
Effective interest on financing obligation	11	0
Issuance of common stock for service rendered	0	17
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	-352	-2,428
Other non-current assets	-213	-1,253
Accounts payable	-1,195	-1,944
Accruals and other current liabilities	1,175	1,813
Payments against Medicis liabilities	0	-7,073
Deferred rent	16	403
Deferred revenue	0	-83
Net cash used in operating activities	-13,026	-21,106
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	-1,801	-985
Change in restricted cash	75	75
Net cash used in investing activities	-1,726	-910
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock, net of deferred initial public offering costs	0	102,672
Proceeds from issuance of convertible notes and notes payable	0	6,750
Principal payments made on capital leases and financing obligation	-84	-2
Principal payments made on notes payable	-2,652	-2,042
Proceeds from the exercise of stock options and employee stock purchase plan	173	15
Payments to settle warrants	0	-1,438
Net cash provided by (used in) financing activities	-2,563	105,955
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-17,315	83,939
CASH AND CASH EQUIVALENTS — Beginning of period	171,032	3,914
CASH AND CASH EQUIVALENTS — End of period	153,717	87,853
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	110	372
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Property and equipment purchases included in accounts payable and accruals and other current liabilities	194	3,594
Conversion of Series E-1, E-2, E-3, E-4 and E-5 preferred stock into common stock	0	123,982
Conversion of 2013 Notes into common stock	0	26,206
Issuance of common stock upon net exercise of common stock warrants in connection with IPO	0	6,490
Fair value in excess of debt host for derivative liabilities associated with convertible notes	0	1,050
Deferred initial public offering costs	0	4,028
Conversion of preferred stock warrants to common stock warrants	0	1,441
Termination of stock option repurchase right	0	58
Issuance of common stock warrants in connection with the 2013 Notes	0	981
Issuance of convertible preferred stock warrants	$0	$80

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company and Basis of Presentation
	Revance Therapeutics, Inc., or the Company, was incorporated in Delaware on August 10, 1999 under the name Essentia Biosystems, Inc. The Company commenced operations in June 2002 and on April 19, 2005, changed its name to Revance Therapeutics, Inc. The Company is a clinical-stage specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. The Company is leveraging its proprietary portfolio of botulinum toxin type A compounds, combined with its patented TransMTS® peptide delivery system to address unmet needs in large and growing neurotoxin markets. Revance's proprietary TransMTS technology enables delivery of botulinum toxin type A through two novel product candidates, topical RT001 and injectable RT002. The Company is pursuing clinical development for RT001 and RT002 in a broad spectrum of aesthetic and therapeutic indications. The Company holds worldwide rights for all indications of RT001, RT002, and its TransMTS technology platform.
	Since commencing operations in 2002, the Company has devoted substantially all of its efforts to identifying and developing product candidates for the aesthetics and therapeutic pharmaceutical markets, recruiting personnel and raising capital. The Company has devoted predominantly all of its resources to preclinical, clinical, and manufacturing development of RT001 and RT002. The Company has never been profitable and has not yet commenced commercial operations.
	Since the Company's inception, the Company has incurred losses and negative cash flows from operations. The Company has not generated significant revenue from product sales to date and will continue to incur significant research and development and other expenses related to its ongoing operations. For the three months ended March 31, 2015, the Company had a net loss of $15.4 million and used $13.0 million of cash for operating activities. As of March 31, 2015, the Company had a working capital surplus of $149.3 million and an accumulated deficit of $274.2 million. The Company has funded its operations primarily through the sale and issuance of common stock, convertible preferred stock, notes payable, and convertible notes. As of March 31, 2015, the Company had capital resources consisting of cash and cash equivalents of $153.7 million. The Company believes that its existing cash and cash equivalents will allow the Company to fund its operations for the next 12 months.
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements, in the opinion of management, include all adjustments which the Company considers necessary for the fair statement of the Condensed Consolidated Results of Operations and Comprehensive Loss and Cash Flows for the interim periods covered and the Condensed Consolidated Financial Position of the Company at the date of the balance sheets. The December 31, 2014 Condensed Consolidated Balance Sheet was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America, or US GAAP. The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2015, or any other future period.
	The Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited Consolidated Financial Statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission, or SEC, on March 4, 2015.
	The Condensed Consolidated Financial Statements of the Company include the Company’s accounts and those of the Company’s wholly-owned subsidiary and have been prepared in conformity with US GAAP.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies
	Significant accounting policies are described in Note 2 to the consolidated financial statements in Item 15 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. There have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2015, except as described in the Accounting Pronouncements section below.
	Use of Estimates
	The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.
	Accounting Pronouncements
	In August 2014, the FASB issued Accounting Standard Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), which will require management to assess an entity’s ability to continue as a going concern at each annual and interim period. Related footnote disclosures will be required if conditions give rise to substantial doubt about an entity’s ability to continue as a going concern within one year of the report issuance date. If conditions do not give rise to substantial doubt, no disclosures will be required specific to going concern uncertainties. The guidance defines substantial doubt using a likelihood threshold of “probable” similar to the current use of that term in U.S. GAAP for loss contingencies and provides example indicators. The guidance is effective for reporting periods ending after December 15, 2016, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on the Company’s financial statements.

Medicis_Settlement

Medicis Settlement	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Medicis Settlement	Medicis Settlement
	In October 2012, the Company entered into a settlement and termination agreement with Medicis Pharmaceutical Corporation, or Medicis. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT001 and RT002 from Medicis and for consideration payable by the Company to Medicis of up to $25.0 million, comprised of (i) an upfront payment of $7.0 million, which was paid in 2012, (ii) a Proceeds Sharing Arrangement Payment of $14.0 million due upon specified capital raising achievements by the Company, of which $6.9 million was paid in 2013 and the remaining $7.1 million was paid in 2014, and (iii) $4.0 million to be paid upon the achievement of specified regulatory milestones by the Company, or Product Approval Payment.
	As of March 31, 2015, the Company determined the fair value of its liability for the Product Approval Payment was $1.6 million, which was measured by assuming a term of 3.25 years, a risk-free rate of 1.0% and a credit risk adjustment of 6.5%. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2018. The Company did not make any payments under the Product Approval Payment during the three months ended March 31, 2015.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements
	The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. These liabilities, consisting of the Medicis settlement, are considered Level 3 instruments, while the assets, consisting of money market funds, are considered Level 1 instruments. The fair value of these instruments was as follows (in thousands):
		March 31, 2015
		Fair Value		Level 1		Level 2		Level 3
	Assets
	Money market funds	$	148,562	$	148,562	$	—	$	—
	Total assets measured at fair value	$	148,562	$	148,562	$	—	$	—
		31-Dec-14
		Fair Value		Level 1		Level 2		Level 3
	Assets
	Money market funds	$	166,038	$	166,038	$	—	$	—
	Total assets measured at fair value	$	166,038	$	166,038	$	—	$	—
		As of March 31, 2015
		Fair Value		Level 1		Level 2		Level 3
	Liabilities
	Derivative liabilities associated with the Medicis settlement	$	1,583	$	—	$	—	$	1,583
	Total liabilities measured at fair value	$	1,583	$	—	$	—	$	1,583
		As of December 31, 2014
		Fair Value		Level 1		Level 2		Level 3
	Liabilities
	Derivative liabilities associated with the Medicis settlement	$	1,541	$	—	$	—	$	1,541
	Total liabilities measured at fair value	$	1,541	$	—	$	—	$	1,541
	The Company did not transfer any assets or liabilities measured at fair value on a recurring basis to or from Level 1 and Level 2 during the three months ended March 31, 2015 and the year ended December 31, 2014.
	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):
		Derivative
		Liability
		Associated with
		the Medicis
		Settlement
	Fair value as of December 31, 2014	1,541
	Change in fair value	42
	Fair value as of March 31, 2015	$	1,583
	The fair value of the derivative liability resulting from the Medicis litigation settlement, specifically the derivative related to the Product Approval Payment (Note 3), was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment. The significant unobservable inputs used in the fair value measurement of the Product Approval Payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	Notes Payable
	Hercules Notes Payable
	In September 2011, the Company entered into a loan and security agreement with Hercules Technology Growth Capital for $22.0 million, referred to as the Hercules Notes Payable. From the proceeds of the Hercules Notes Payable, the Company used $7.0 million to fully repay the principal and accrued interest due under two secured promissory notes, or Venture Debt, with two venture debt lenders. At the time of the Venture Debt repayment, the remaining unamortized debt discount of $0.6 million was written-off to interest expense.
	The Hercules Notes Payable, which matured in March 2015 and has been repaid in full, was collateralized by all assets of the Company, and bore interest at the greater of (i) 9.85% per annum or (ii) 9.85% per annum plus the difference of the prime rate less 3.25% per annum and contains covenants that require, among other things, that the Company seek consent from Hercules prior to certain corporate changes and provide certain unaudited financial information within 45 days after the end of each quarter and within 90 days after each year end. Starting in July 2012, the loan was repaid in 33 equal monthly payments of principal and interest of $0.8 million plus an end of term payment of $0.5 million if the loan is prepaid, or $0.4 million if paid upon maturity. In March 2015, the Hercules Notes Payable was repaid in full, including the end of term payment of $0.4 million.
	In connection with the Hercules Notes Payable, the Company issued warrants to purchase 17,977 shares of Series D convertible preferred stock at $66.75 per share, which converted to warrants to purchase common stock upon the Company's initial public offering, or IPO. The fair value of the warrants of $0.1 million was recorded as a debt discount and is amortized to interest expense using the straight-line method over the loan term. The Company recognized interest expense of $0.01 million and $0.01 million from the amortization of the warrant related debt discount for the three months ended March 31, 2015 and 2014, respectively. The unamortized debt discount balances were $0 and $0.01 million as of March 31, 2015 and December 31, 2014, respectively. The Company incurred $0.5 million of debt issuance costs in connection with the Hercules Notes Payable which was also being amortized to interest expense over the term of the borrowings. The Company recognized interest expense of $0.04 million from the amortization of the debt issuance costs during each of the three months ended March 31, 2015 and 2014, respectively. The unamortized debt issuance costs balances were $0 and $0.04 million as of March 31, 2015 and December 31, 2014, respectively.
	The Company made principal and interest payments on the Hercules Notes Payable of $2.6 million and $2.3 million during the three months ended March 31, 2015 and 2014, respectively.
	Essex Capital Notes
	On December 20, 2013, the Company signed a Loan and Lease Agreement to borrow up to $10.8 million in the form of Secured Promissory Notes from Essex Capital, or the Essex Notes, to finance the completion and installation of the Company’s RT001 commercial fill/finish line, or the Fill/Finish Line. Under the Loan and Lease Agreement, with the issuance of each Note, the Company issued warrants to purchase its capital stock. The Essex Notes incurred interest at 11.5% per annum through the completion of the IPO in February 2014 and 10.375% per annum thereafter. In December 2013, the Company drew down $2.5 million under short-term notes pursuant to the Essex Capital Facility, and an additional $2.5 million in January 2014 under short-term notes. In May 2014, pursuant to the terms of this agreement, the Company sold equipment to Essex Capital, resulting in partial settlement of the outstanding loan balance by $1.1 million. Pursuant to the Loan and Lease Agreement, the Company sold and leased the equipment back from Essex Capital. This transaction does not qualify for sale-leaseback accounting due to the Company’s continuing involvement in the equipment. Therefore, the Company accounted for this transaction as a financing obligation using the effective interest rate method. As of March 31, 2015, the aggregate total future minimum lease payments under the financing obligation were as follows (in thousands):
	Year Ending December 31,
	2015	317
	2016	423
	2017	141
	Total payments	881
	On December 17, 2014, the Company entered into the First Amendment to the Loan and Lease Agreement with Essex Capital. Under the terms of this Amendment, the Company repaid the outstanding debt balance of $3.9 million and issued warrants to purchase 44,753 shares of common stock. In February 2015, the Company executed the Second Amendment to the Loan and Lease Agreement, under which the term of the facility was extended to April 15, 2015, and the purchase price of the equipment was increased by $0.1 million to approximately $9.8 million. In accordance with the terms of the Loan and Lease Agreement, in April 2015, the Company sold equipment to Essex Capital for approximately $9.8 million, and concurrently with this sale, entered into a lease for the equipment for a fixed monthly payment to be paid over 3 years. At the end of the lease, the Company will have the option to purchase the leased equipment for 10% of the original purchase amount.
	Additionally, the Company made interest payments on the Essex Notes in the amount of $0.01 million for the three months ended March 31, 2014.

Convertible_Notes_Warrants_and

Convertible Notes, Warrants, and Related Derivatives	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Convertible Notes, Warrants, and Related Derivatives	Convertible Notes, Warrants, and Related Derivatives
	2013 Convertible Notes, Common Stock Warrants, and Related Derivatives
	In February 2014, in connection with the Company’s IPO, the 2013 Notes with a principal amount of $23.7 million, accrued interest through the date of the IPO, remaining interest due through October 7, 2014, and derivative liability totaling $26.2 million converted into 1,637,846 shares of the Company’s common stock.
	In connection with the issuance of the 2013 Notes, the Company issued warrants to purchase 409,450 shares of common stock, which were net exercised for 405,594 shares of common stock upon the IPO.
	Additionally, the 2013 Notes had conversion and redemption features which were determined to be embedded derivatives, requiring bifurcation and separate fair value accounting. Immediately prior to the conversion, the Company determined that the fair value of the derivative liabilities associated with the convertible notes was reduced to $1.9 million, the value of interest due to note holders from the date of the IPO through the maturity date of the loan in October 2014.
	Upon the conversion of the 2013 Notes into shares of common stock, the Company applied extinguishment accounting resulting in a loss of $8.3 million. As of the date of conversion, the Company was in compliance with all covenants in the 2013 Notes.
	During the three months ended March 31, 2014, the Company recognized non-cash interest expense of $9.6 million related to the 2013 Notes, including amortization of warrant-related debt discount of approximately $0.4 million up to the date of conversion, amortization of the derivative-related debt discount of $0.6 million up to the date of conversion, accrued interest of $0.3 million up to the date of conversion and a loss on extinguishment of $8.3 million upon conversion of the 2013 Notes into common stock.

Interest_Expense

Interest Expense	3 Months Ended
	Mar. 31, 2015
Other Income and Expenses [Abstract]
Interest Expense	Interest Expense
	Interest expense, includes cash and non-cash components with the non-cash components consisting of (i) interest recognized from the amortization of debt issuance costs, which were capitalized on the Condensed Consolidated Balance Sheets and are generally derived from cash payments related to the issuance of convertible notes and notes payable, (ii) interest recognized from the amortization of debt discounts, which were capitalized on the Condensed Consolidated Balance Sheets and derived from the issuance of warrants and derivatives issued in conjunction with convertible notes and notes payable, (iii) interest recognized on the 2013 convertible notes, or 2013 Notes, which was not paid but rather converted into shares of common stock, (iv) interest capitalized for assets constructed for use in operations, (v) interest related to the extinguishment of debt, which is classified as a loss on debt extinguishments, and (vi) effective interest recognized on the financing obligation. The capitalized amounts related to the debt issuance costs and debt discounts are generally amortized to interest expense over the term of the related debt instruments.
	The interest expense by cash and non-cash components is as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Interest expense
	Cash related interest expense (1)	$	(110	)	$	(372	)
	Non-cash interest expense
	Non-cash interest expense — debt issuance costs	(39		)	(52		)
	Non-cash interest expense — warrant and derivative related debt discounts	(5		)	(67		)
	Non-cash interest expense — convertible notes	—			(1,250		)
	Loss on extinguishment of 2013 Notes	—			(8,331		)
	Effective interest on financing obligation	(11		)	—
	Non-cash capitalized interest expense (2)	—			231
	Total non-cash interest expense	(55		)	(9,469		)
	Total interest expense	$	(165	)	$	(9,841	)
	-1	Cash related interest expense included interest payments to Hercules Notes Payable and Essex Notes.
	-2	Interest expense capitalized pursuant to Accounting Standards Codification Topic 835, Interest.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Facility Lease
	In January 2010, the Company entered into a non-cancelable facility lease that requires monthly payments through January 2022. This facility will be used for research, manufacturing, and administrative functions.
	In February 2014, the Company extended the term of the Lease by thirty-six (36) months to January 2025. Under the terms of the lease agreement, the payments escalate over the term of the lease with the exception of a decrease in payments at the beginning of 2022, however, the Company recognizes the expense on a straight-line basis over the life of the lease.
	Rent expense was $1.3 million for each of the three months ended March 31, 2015 and 2014. As of March 31, 2015, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands):
	Year Ending December 31,
	2015	$	3,807
	2016	5,222
	2017	5,394
	2018	5,578
	2019 and thereafter	32,354
	Total payments	$	52,355
	Other Milestone-Based Commitments
	The Company has one remaining obligation to make a future milestone payment to List Laboratories that becomes due and payable on the achievement of a certain regulatory milestone. The Company is obligated to pay royalties to List Laboratories on future sales of botulinum toxin products.
	Purchase Commitments
	The Company has certain commitments from outstanding purchase orders primarily related to clinical trial development and other costs related to the Company’s manufacturing facility. These agreements, which total $21.7 million, are cancellable at any time with the Company required to pay all costs incurred through the cancellation date.
	Contingencies
	From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. As of May 2015, the Company became subject to a legal compliant, captioned City of Warren Police and Fire Retirement System v. Revance Therapeutics Inc., et al, CIV 533635, which was filed on behalf of City of Warren Police and Fire Retirement System in the Superior Court for San Mateo County, California against the Company and certain of its directors and executive officers at the time of the follow-on public offering, and the investment banking firms that acted as the underwriters in the follow-on public offering. In general, the complaint alleges that the defendants misrepresented the then-present status of the RT001 clinical program and made false and misleading statements regarding the formulation, manufacturing and efficacy of its drug candidate, RT001, for the treatment of lateral canthal lines at the time of the follow-on public offering. The complaint has been brought as a purported class action on behalf of those who purchased common stock in the follow-on public offering and seeks unspecified monetary damages and other relief.
	The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. At this time, neither the outcome of this matter, nor an estimate of the maximum potential exposure or the range of possible loss can be determined. The Company believes that the class action lawsuit is without merit and intends to vigorously defend the action. Nevertheless, this litigation, as any other litigation, is subject to uncertainty and there can be no assurance that this litigation will not have a material adverse effect on the Company's business, results of operations, financial position or cash flows.
	Indemnification
	The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.
	The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.
	No amounts associated with such indemnifications have been recorded to date.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2015
Warrants and Rights Note Disclosure [Abstract]
Warrants	Warrants
	As of March 31, 2015, the Company has warrants to purchase 198,662 shares of common stock outstanding and no convertible preferred stock warrants outstanding.

Stock_Option_Plans

Stock Option Plans	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Plans	Stock Option Plans
	2014 Equity Incentive Plan
	On January 1, 2015, the number of shares of common stock reserved for issuance under the Company’s 2014 Equity Incentive Plan, or 2014 EIP, automatically increased by 4% of the total number of shares of the Company’s capital stock outstanding on December 31, 2014, or 950,978 shares. During the first quarter of 2015, the Company granted stock options for 543,838 shares of common stock and 142,986 restricted stock awards under the 2014 EIP to employees, including a stock option grant for 18,000 shares to a new board member. As of March 31, 2015, there were 359,138 shares available for issuance under the 2014 EIP.
	2014 Inducement Plan
	As of March 31, 2015, there were 141,500 shares available for issuance under the 2014 Inducement Plan, or 2014 IN.
	The fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected term (in years)	6		6
	Expected volatility	62.7	%	59.1	%
	Risk-free interest rate	1.4	%	1.3	%
	Expected dividend rate	0	%	0	%
	Fair Value of Common Stock. The fair value of the shares of common stock is based on the Company's stock price. Prior to the IPO, the fair value of the shares of common stock underlying the stock options has historically been determined by the Board of Directors. Because there was no public market for the Company’s common stock, the Board of Directors had determined fair value of the common stock at the time of grant of the option by considering a number of objective and subjective factors including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, amongst other factors.
	Expected Term. The expected term for employees and directors is based on the simplified method, as the Company’s stock options have the following characteristics: (i) granted at-the-money; (ii) exercisability is conditioned upon service through the vesting date; (iii) termination of service prior to vesting results in forfeiture; (iv) limited exercise period following termination of service; and (v) options are non-transferable and non-hedgeable, or “plain vanilla” options, and the Company has limited history of exercise data. The expected term for non-employees is based on the remaining contractual term.
	Expected Volatility. Since the Company was a private entity until February 2014 with no historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available.
	Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury constant maturity rates with remaining terms similar to the expected term of the options.
	Expected Dividend Rate. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend rate of zero in the valuation model.
	Forfeitures. The Company is required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and record stock based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.
	The fair value of the stock options granted to non-employees is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected term (in years)	9		5.1
	Expected volatility	64	%	54.5	%
	Risk-free interest rate	1.9	%	1.7	%
	Expected dividend rate	0	%	0	%
	2014 Employee Stock Purchase Plan
	On January 1, 2015, the number of shares of common stock reserved for issuance under the Company’s 2014 Employee Stock Purchase Plan, or 2014 ESPP, automatically increased by 1% of the total number of shares of the Company’s capital stock outstanding on December 31, 2014, or 237,744 shares. As of March 31, 2015, there were 412,405 shares available for issuance under the 2014 EIP.
	The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected term (in years)	0.5		0.5
	Expected volatility	49.9	%	48	%
	Risk-free interest rate	0.1	%	0.1	%
	Expected dividend rate	—	%	—	%
	Fair Value of Common Stock. The fair value of the shares of common stock is based on the Company’s stock price.
	Expected Term. The expected term is based on the term of the purchase period under the 2014 ESPP.
	Expected Volatility. Since the Company was a private entity until February 2014 with no historical data regarding the volatility of its common stock, the expected volatility used is based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, capital structure, and size. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available.
	Risk-Free Interest Rate. The risk-free interest rate is based on U.S. Treasury constant maturity treasury rates with remaining terms similar to the expected term.
	Expected Dividend Rate. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend rate of zero in the valuation model.
	Total Stock-Based Compensation
	Total stock-based compensation expense related to options granted to employees and nonemployees was allocated as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Research and development	$	828		$	495
	General and administrative	1,489			315
	Total stock based compensation expense	$	2,317		$	810

Net_Loss_per_Share_Attributabl

Net Loss per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders
	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2015 and 2014 (in thousands, except for share and per share amounts):
		Three Months Ended
		March 31,
		2015				2014
	Net loss attributable to common stockholders, basic	$	(15,402	)		$	(21,426	)
	Net loss attributable to common stockholders, diluted	$	(15,402	)		$	(21,426	)
	Net loss per share attributable to common stockholders
	Basic	$	(0.65	)		$	(1.93	)
	Diluted	$	(0.65	)		$	(1.93	)
	Weighted-average shares used in computing net loss per share attributable to common stockholders:
	Basic	23,535,080				11,092,471
	Diluted	23,535,080				11,092,471
	The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:
		As of March 31,
		2015			2014
	Stock options	2,331,401			1,239,817
	Common stock warrants	198,662			173,975
	Shares expected to be purchased on June 30 under the 2014 ESPP	8,532			22,114

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events
	In April 2015, in accordance with the Second Amendment to the Loan and Lease Agreement with Essex Capital, the Company sold equipment to Essex Capital for approximately $9.8 million, and concurrently with this sale, entered into a lease for such equipment for a fixed monthly payment to be paid over 3 years (Note 5). At the end of the lease, the Company will have the option to purchase the leased equipment for 10% of the original purchase amount.
	On April 23, 2015, the Company received notice from Valeant terminating the royalty agreement dated as of August 5, 2011 by and between the Company and Precision Dermatology, Inc. effective as of July 23, 2015. Precision Dermatology, Inc. was acquired by Valeant Pharmaceuticals International, Inc. in July 2014. The rights to the Relastin® product line will revert back to the Company upon termination of the agreement.
	In May 2015, the Company became subject to a legal compliant (Note 8). At this time, neither the outcome of this matter, nor an estimate of the maximum potential exposure or the range of possible loss can be determined.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates
	The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include the fair value of common stock, stock-based compensation, fair value of convertible preferred stock and warrants, fair value of derivatives, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and also on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Instruments	The fair value of these instruments was as follows (in thousands):
		March 31, 2015
		Fair Value		Level 1		Level 2		Level 3
	Assets
	Money market funds	$	148,562	$	148,562	$	—	$	—
	Total assets measured at fair value	$	148,562	$	148,562	$	—	$	—
		31-Dec-14
		Fair Value		Level 1		Level 2		Level 3
	Assets
	Money market funds	$	166,038	$	166,038	$	—	$	—
	Total assets measured at fair value	$	166,038	$	166,038	$	—	$	—
		As of March 31, 2015
		Fair Value		Level 1		Level 2		Level 3
	Liabilities
	Derivative liabilities associated with the Medicis settlement	$	1,583	$	—	$	—	$	1,583
	Total liabilities measured at fair value	$	1,583	$	—	$	—	$	1,583
		As of December 31, 2014
		Fair Value		Level 1		Level 2		Level 3
	Liabilities
	Derivative liabilities associated with the Medicis settlement	$	1,541	$	—	$	—	$	1,541
	Total liabilities measured at fair value	$	1,541	$	—	$	—	$	1,541
Summary of Changes in Fair Value of Financial Instruments	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):
		Derivative
		Liability
		Associated with
		the Medicis
		Settlement
	Fair value as of December 31, 2014	1,541
	Change in fair value	42
	Fair value as of March 31, 2015	$	1,583

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation	As of March 31, 2015, the aggregate total future minimum lease payments under the financing obligation were as follows (in thousands):
	Year Ending December 31,
	2015	317
	2016	423
	2017	141
	Total payments	881

Interest_Expense_Tables

Interest Expense (Tables)	3 Months Ended
	Mar. 31, 2015
Other Income and Expenses [Abstract]
Summary of Interest Expense by Cash and Non-Cash Components	The interest expense by cash and non-cash components is as follows (in thousands):
		Three Months Ended March 31,
		2015			2014
	Interest expense
	Cash related interest expense (1)	$	(110	)	$	(372	)
	Non-cash interest expense
	Non-cash interest expense — debt issuance costs	(39		)	(52		)
	Non-cash interest expense — warrant and derivative related debt discounts	(5		)	(67		)
	Non-cash interest expense — convertible notes	—			(1,250		)
	Loss on extinguishment of 2013 Notes	—			(8,331		)
	Effective interest on financing obligation	(11		)	—
	Non-cash capitalized interest expense (2)	—			231
	Total non-cash interest expense	(55		)	(9,469		)
	Total interest expense	$	(165	)	$	(9,841	)
	-1	Cash related interest expense included interest payments to Hercules Notes Payable and Essex Notes.
	-2	Interest expense capitalized pursuant to Accounting Standards Codification Topic 835, Interest.

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases	As of March 31, 2015, the aggregate total future minimum lease payments under non-cancelable operating leases were as follows (in thousands):
	Year Ending December 31,
	2015	$	3,807
	2016	5,222
	2017	5,394
	2018	5,578
	2019 and thereafter	32,354
	Total payments	$	52,355

Stock_Option_Plans_Tables

Stock Option Plans (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Fair Value Assumptions	The fair value of the employee stock options under the 2014 EIP and 2014 IN was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected term (in years)	6		6
	Expected volatility	62.7	%	59.1	%
	Risk-free interest rate	1.4	%	1.3	%
	Expected dividend rate	0	%	0	%
	The fair value of the stock options granted to non-employees is calculated at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected term (in years)	9		5.1
	Expected volatility	64	%	54.5	%
	Risk-free interest rate	1.9	%	1.7	%
	Expected dividend rate	0	%	0	%
	The fair value of the option component of the shares purchased under the 2014 ESPP was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions:
		Three Months Ended
		March 31,
		2015		2014
	Expected term (in years)	0.5		0.5
	Expected volatility	49.9	%	48	%
	Risk-free interest rate	0.1	%	0.1	%
	Expected dividend rate	—	%	—	%
Schedule of Stock-based Compensation Expense	Total stock-based compensation expense related to options granted to employees and nonemployees was allocated as follows (in thousands):
		Three Months Ended
		March 31,
		2015			2014
	Research and development	$	828		$	495
	General and administrative	1,489			315
	Total stock based compensation expense	$	2,317		$	810

Net_Loss_per_Share_Attributabl1

Net Loss per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders for the three months ended March 31, 2015 and 2014 (in thousands, except for share and per share amounts):
		Three Months Ended
		March 31,
		2015				2014
	Net loss attributable to common stockholders, basic	$	(15,402	)		$	(21,426	)
	Net loss attributable to common stockholders, diluted	$	(15,402	)		$	(21,426	)
	Net loss per share attributable to common stockholders
	Basic	$	(0.65	)		$	(1.93	)
	Diluted	$	(0.65	)		$	(1.93	)
	Weighted-average shares used in computing net loss per share attributable to common stockholders:
	Basic	23,535,080				11,092,471
	Diluted	23,535,080				11,092,471
Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share	The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:
		As of March 31,
		2015			2014
	Stock options	2,331,401			1,239,817
	Common stock warrants	198,662			173,975
	Shares expected to be purchased on June 30 under the 2014 ESPP	8,532			22,114

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company's incorporation date	10-Aug-99
Commencement date of operations	30-Jun-02
Change of entity name date	19-Apr-05
Net loss	$15,402,000	$21,426,000
Net cash used in operating activities	13,026,000	21,106,000
Working capital surplus	149,300,000
Accumulated deficit	-274,199,000		-258,797,000
Cash and cash equivalents	$153,717,000	$87,853,000	$171,032,000	$3,914,000
Cash and cash equivalents, expected funding term for operating plan	12 months

Medicis_Settlement_Additional_

Medicis Settlement - Additional Information (Detail) (Medicis Pharmaceutical Corporation, USD $)	1 Months Ended	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Oct. 31, 2012	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Settlement And Termination [Line Items]
Settlement consideration payable	$25
Upfront payment paid	7
Proceeds Sharing Arrangement
Settlement And Termination [Line Items]
Settlement agreement, payable	14
Settlement payment			7.1	6.9
Remaining contractual term (in years)		3 years 3 months
Risk-free interest rate		1.00%
Fair value assumptions, credit risk adjustment		6.50%
Product Approval Payment Derivative
Settlement And Termination [Line Items]
Settlement agreement, payable	4
Fair value of derivative		1.6

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$148,562	$166,038
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	148,562	166,038
Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	148,562	166,038
Total liabilities measured at fair value	0	0
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	148,562	166,038
Level 1 | Derivative liabilities associated with the Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Total liabilities measured at fair value	0	0
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 2 | Derivative liabilities associated with the Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Total liabilities measured at fair value	1,583	1,541
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0	0
Level 3 | Derivative liabilities associated with the Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	1,583	1,541
Recurring
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	1,583	1,541
Recurring | Derivative liabilities associated with the Medicis settlement
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	$1,583	$1,541

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) (Derivative liabilities associated with the Medicis settlement, USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Derivative liabilities associated with the Medicis settlement
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value as of December 31, 2014	$1,541
Change in fair value	42
Fair value as of March 31, 2015	$1,583

Notes_Payable_Hercules_Notes_P

Notes Payable - Hercules Notes Payable (Detail) (USD $)	1 Months Ended	3 Months Ended
	Sep. 30, 2011	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
		monthly_payment
Debt Instrument [Line Items]
Proceeds from notes payable		$0	$6,750,000
Payments made on notes payable		2,652,000	2,042,000
Interest paid		110,000	372,000
Hercules Notes Payable
Debt Instrument [Line Items]
Proceeds from notes payable	22,000,000
Unamortized debt discount		0		10,000
Notes payable maturity		31-Mar-15
Interest rate, percentage		9.85%
Notes payable repayment start date		31-Jul-12
Notes payable repayment terms		33
Payment of notes payable principal and interest		800,000
Prepayment charge on end of term payment		500,000
End of term payment		400,000
Warrants issued to purchase shares		17,977
Exercise price per share		$66.75
Debt discount amortized		100,000
Recognition of interest expense from warrant related debt discount		10,000	10,000
Debt issuance costs		500,000
Amortization of debt issuance costs		40,000	40,000
Unamortized debt issuance costs		0		40,000
Payments made on notes payable			2,600,000
Interest paid			2,300,000
Hercules Notes Payable | Prime Rate
Debt Instrument [Line Items]
Plus (minus) difference from the prime rate		3.25%
Venture Debt
Debt Instrument [Line Items]
Repayment of debt	7,000,000
Unamortized debt discount	$600,000

Notes_Payable_Essex_Capital_No

Notes Payable - Essex Capital Notes (Detail) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 28, 2015	31-May-14	Apr. 30, 2015	Dec. 17, 2014	Feb. 28, 2014	Jan. 31, 2014	Dec. 20, 2013
Debt Instrument [Line Items]
Interest paid	$110,000	$372,000
Essex Notes
Debt Instrument [Line Items]
Secured promissory notes, able to borrow (up to)									10,800,000
Interest rate, percentage							10.38%		11.50%
Short-term notes		2,500,000						2,500,000
Settlement of outstanding loan balance				1,100,000
Notes payable						3,900,000
Shares available for purchase under common stock warrants						44,753
Equipment Purchased by Third Party, Increase During Period			100,000
Interest paid		10,000
Essex Notes | Subsequent Event
Debt Instrument [Line Items]
Equipment purchased by third party					$9,800,000
Lease period					3 years
Percentage of original purchase amount of asset at end of lease					10.00%

Notes_Payable_Summary_of_Aggre

Notes Payable - Summary of Aggregate Total Future Minimum Lease Payments under the Financing Obligation (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
2015	$317
2016	423
2017	141
Total payments	$881

Convertible_Notes_Warrants_and1

Convertible Notes, Warrants, and Related Derivatives - Additional Information (Detail) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Feb. 28, 2014	Oct. 31, 2013
Debt Instrument [Line Items]
Gain (loss) on debt extinguishment	$0	($8,331,000)
Interest expense	0	271,000
Amortization of debt discount	5,000	1,046,000
Interest expense, excluding amortization of debt discount	110,000	372,000
2013 Notes
Debt Instrument [Line Items]
Shares available for purchase under common stock warrants				409,450
Shares issued upon exercise of warrants (in shares)			405,594
Fair value of embedded derivative liability			1,900,000
Gain (loss) on debt extinguishment			-8,300,000
Interest expense		9,600,000
Interest expense, excluding amortization of debt discount		300,000
2013 Notes, Warrant
Debt Instrument [Line Items]
Amortization of debt discount		400,000
2013 Notes, Embedded Derivative Liability
Debt Instrument [Line Items]
Amortization of debt discount		600,000
Convertible Debt | 2013 Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount			23,700,000
Convertible debt			$26,200,000
Shares issued upon debt conversion (in shares)			1,637,846

Interest_Expense_Summary_of_In

Interest Expense - Summary of Interest Expense by Cash and Non-Cash Components (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Other Income and Expenses [Abstract]
Cash related interest expense	($110)	($372)
Non-cash interest expense
Non-cash interest expense — debt issuance costs	-39	-52
Non-cash interest expense — warrant and derivative related debt discounts	-5	-67
Non-cash interest expense — convertible notes	0	-1,250
Loss on extinguishment of 2013 Notes	0	-8,331
Effective interest on financing obligation	-11	0
Non-cash capitalized interest expense	0	231
Total non-cash interest expense	-55	-9,469
Total interest expense	($165)	($9,841)

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Feb. 28, 2014	Mar. 31, 2015	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Extended term of lease	36 months
Rent expense		$1.30	$1.30
Purchase commitments		$21.70

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
2015	$3,807
2016	5,222
2017	5,394
2018	5,578
2019 and thereafter	32,354
Total payments	$52,355

Warrants_Additional_Informatio

Warrants - Additional Information (Detail)	Mar. 31, 2015
Common Stock
Class of Warrant or Right [Line Items]
Common stock warrants	198,662
Convertible preferred stock warrants
Class of Warrant or Right [Line Items]
Number of shares underlying warrants	0

Stock_Option_Plans_Additional_

Stock Option Plans - Additional Information (Detail)	0 Months Ended	3 Months Ended
	Jan. 01, 2015	Mar. 31, 2015
2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding stock	4.00%
2014 Equity Incentive Plan | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares outstanding increase during period	950,978
Shares underlying stock options granted		543,838
Shares available for issuance		359,138
2014 Equity Incentive Plan | Restricted Stock Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted		142,986
2014 Equity Incentive Plan | Board Member | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted		18,000
2014 Inducement Plan | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance		141,500
2014 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding stock	1.00%
Common stock shares outstanding increase during period	237,744
Shares available for issuance		412,405

Stock_Option_Plans_Fair_Value_

Stock Option Plans - Fair Value Assumptions (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
2014 Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 months	6 months
Expected volatility	49.90%	48.00%
Risk-free interest rate	0.10%	0.10%
Expected dividend rate	0.00%	0.00%
2014 Inducement Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years	6 years
Expected volatility	62.70%	59.10%
Risk-free interest rate	1.40%	1.30%
Expected dividend rate	0.00%	0.00%
2014 Inducement Plan | Non-employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	9 years	5 years 1 month 6 days
Expected volatility	64.00%	54.50%
Risk-free interest rate	1.90%	1.70%
Expected dividend rate	0.00%	0.00%

Stock_Option_Plans_Schedule_of

Stock Option Plans - Schedule of Stock-based Compensation Expense (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	$2,317	$810
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	828	495
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock based compensation expense	$1,489	$315

Net_Loss_per_Share_Attributabl2

Net Loss per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Net loss attributable to common stockholders, basic	($15,402)	($21,426)
Net loss attributable to common stockholders, diluted	($15,402)	($21,426)
Net income (loss) per share attributable to common stockholders
Basic (in dollars per share)	($0.65)	($1.93)
Diluted (in dollars per share)	($0.65)	($1.93)
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders:
Basic (in shares)	23,535,080	11,092,471
Diluted (in shares)	23,535,080	11,092,471

Net_Loss_per_Share_Attributabl3

Net Loss per Share Attributable to Common Stockholders - Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share	2,331,401	1,239,817
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share	198,662	173,975
Shares expected to be purchased on June 30 under the 2014 ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share	8,532	22,114

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (Essex Notes, USD $)	1 Months Ended
In Millions, unless otherwise specified	Apr. 30, 2015
Subsequent Event
Subsequent Event [Line Items]
Equipment purchased by third party	$9.80
Lease period	3 years
Percentage of original purchase amount of asset at end of lease	10.00%
Scenario, Forecast
Subsequent Event [Line Items]
Lease period	3 years
Percentage of original purchase amount of asset at end of lease	10.00%
Scenario, Forecast | Subsequent Event
Subsequent Event [Line Items]
Equipment purchased by third party	$9.80